Tucatinib

Drug Profile

Tucatinib

Alternative Names: ARRY-380; Irbinitinib; ONT-380

Latest Information Update: 01 Mar 2017

Price : $50

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; Cascadian Therapeutics; Dana-Farber Cancer Institute
  • Class 2 ring heterocyclic compounds; Antineoplastics; Diamines; Furans; Pyridines; Quinazolinones; Small molecules; Triazoles
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Breast cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer
  • Phase I Solid tumours
  • Phase Unknown Colorectal cancer

Most Recent Events

  • 21 Feb 2017 University of Colorado plans a phase I/II trial for Breast cancer (Combination therapy, Metastatic disease, Inoperable/Unresectable) in USA (NCT03054363)
  • 02 Feb 2017 Academic and Community Cancer Research United, Cascadian Therapeutics and National Cancer Institute plan the phase II MOUNTAINEER trial for Colorectal cancer (Metastatic disease, Combination therapy, Inoperable/Unresectable, Second-line therapy or greater) in USA (PO) (NCT03043313)
  • 31 Jan 2017 Investigation in Colorectal cancer in USA (PO) before January 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top